Literature DB >> 1960854

Treatment schedule dependency of antitumor effect of deoxyspergualin.

K Nishikawa1, C Shibasaki, K Takahashi, T Takeuchi.   

Abstract

The effect of treatment schedule on antitumor activity of 15-deoxyspergualin (NKT-01) against P388 leukemia was studied by changing each 2 out of 3 factors of administration schedule (number of injections, injection interval, and injection period) with the rest being constant. The antitumor activity of NKT-01 was shown to be strongly time-dependent; higher efficacy was obtained with prolongation of treatment period and with increasing the number of injections. The dosing interval seemed not to be a dominant factor regarding the activity of NKT-01. The strong dependency on treatment period was also observed in continuous infusion schedules by using Alzet 2001 osmotic minipump. The degree of dependency on infusion period was estimated to be 3- to 4-fold stronger than that on the infused dose by logarithmical plotting of the infusion periods and infused daily doses required to produce 130% of T/C(%). The effective dose range by the continuous infusion was slightly narrower than that by the repeated bolus injections, although slightly higher maximal activity was obtained at the optimal dose. Hyperacute pharmacological toxicity caused by bolus injection of high dose (51.2 mg/kg) of NKT-01 did not occur by continuous infusion method even at much higher dose (409.6 mg/kg/day). Cumulative gastrointestinal toxicity was observed by prolonged continuous infusion as well as repetitive treatment schedule. From these results on antitumor activity and toxicity by various treatment schedules, recommendable clinical modality for NKT-01 seems to be the short-time infusion on every or every other day continuing for a few weeks.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1960854

Source DB:  PubMed          Journal:  Jpn J Antibiot        ISSN: 0368-2781


  3 in total

Review 1.  The efficiency concept in pharmacodynamics.

Authors:  G Alván; G Paintaud; M Wakelkamp
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

2.  Phase II study of deoxyspergualin in metastatic breast cancer.

Authors:  K Dhingra; V Valero; L Gutierrez; R Theriault; D Booser; F Holmes; A Buzdar; G Fraschini; G Hortobagyi
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

3.  Phase I study of NKT-01.

Authors:  K Tamura; H Niitani; M Oguro; R Ohno; K Sanpi; H Majima; T Masaoka; I Kimura; J Inagaki; Y Suzuoki
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.